Earnings Summary

Stoke Therapeutics’s revenue fell -176.79% since last year same period to $-2.48Mn in the Q2 2023. On a quarterly growth basis, Stoke Therapeutics has generated -148.16% fall in its revenue since last 3-months.

Stoke Therapeutics’s net profit fell -24.35% since last year same period to $-30.65Mn in the Q2 2023. On a quarterly growth basis, Stoke Therapeutics has generated -67.54% fall in its net profits since last 3-months.

Stoke Therapeutics’s net profit margin jumped 261.94% since last year same period to 1235.55% in the Q2 2023. On a quarterly growth basis, Stoke Therapeutics has generated 447.9% jump in its net profit margins since last 3-months.

Stoke Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.71 - a -4.41% fall from last quarter’s estimates.

Stoke Therapeutics’s earning per share (EPS) estimates for the current year stand at -0.71.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Stoke Therapeutics’s return on assets (ROA) stands at -0.25.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Stoke Therapeutics’s return on equity (ROE) stands at -0.51.